Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Related REGN
UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Ahead Of Conference Call
Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
Related AGN
Allergan Comments On Pershing Square's Delivery Of Additional Requests From Stockholders Owning 1.5% Of Allergan's Shares
Bill Ackman Rips Allergan, Inc. In Letter
Allergan to Slash 13% of its Global Workforce (Fox Business)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Sep 2014Credit SuisseMaintainsOutperform
Sep 2014Brean CapitalMaintainsBuy
Aug 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters